3
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A review of the presentation and outcome of left ventricular thrombus in coronavirus disease 2019 infection

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background:

          Cardiovascular complications of the coronavirus disease 2019 (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2), have been documented both in the acute phase and in convalescence. One such complication is the formation of the left ventricular (LV) thrombus. There is a lack of clarity regarding the incidence, risk factors, and management of this complication.

          Aim:

          The aim of the study is to identify the clinical presentation, risk factors and outcome of COVID-19 patients with left ventricular thrombus (LVT).

          Methods:

          A literature search was conducted to identify all case reports of COVID-19 with LVT in PubMed/Medline, Embase, Web of Science, and Google Scholar.

          Results:

          Among the 65 patients identified, 60 had LVT, either at admission, or during the acute phase of the illness. Six patients with mild symptoms during the acute phase of viral illness had only the COVID-19 antibody test positivity at the time LV thrombus was detected. Few of the patients (23.1%) had no comorbidities. The mean age of the patients was 52.8 years, and the youngest patient was 4 years old. This suggests that LVT formation can occur in young COVID-19 patients with no co-morbid conditions. Most of the patients (69.2%) had more than one site of thrombosis. A mortality rate of 23.1% was observed in our review, and ST-elevation myocardial infarction (STEMI) was diagnosed in 33.3% of those who died.

          Conclusions:

          A high degree of suspicion for LVT must be maintained in patients with known cardiac disease and those with new-onset arterial or venous thromboembolism, and such patients may benefit from a screening echocardiography at admission.

          Relevance for Patients:

          The patients with preexisting cardiovascular disease must take added precautions to prevent acquiring COVID-19 infection as there is a higher risk of developing LV thrombus. In patients who develop LVT in COVID-19, mortality rate is higher.

          Related collections

          Most cited references104

          • Record: found
          • Abstract: found
          • Article: not found

          Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

          Highlights • COVID -19 cases are now confirmed in multiple countries. • Assessed the prevalence of comorbidities in infected patients. • Comorbidities are risk factors for severe compared with non-severe patients. • Help the health sector guide vulnerable populations and assess the risk of deterioration.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            COVID-19 and its implications for thrombosis and anticoagulation

            Severe acute respiratory syndrome coronavirus 2, coronavirus disease 2019 (COVID-19)-induced infection can be associated with a coagulopathy, findings consistent with infection-induced inflammatory changes as observed in patients with disseminated intravascular coagulopathy (DIC). The lack of prior immunity to COVID-19 has resulted in large numbers of infected patients across the globe and uncertainty regarding management of the complications that arise in the course of this viral illness. The lungs are the target organ for COVID-19; patients develop acute lung injury that can progress to respiratory failure, although multiorgan failure can also occur. The initial coagulopathy of COVID-19 presents with prominent elevation of D-dimer and fibrin/fibrinogen-degradation products, whereas abnormalities in prothrombin time, partial thromboplastin time, and platelet counts are relatively uncommon in initial presentations. Coagulation test screening, including the measurement of D-dimer and fibrinogen levels, is suggested. COVID-19–associated coagulopathy should be managed as it would be for any critically ill patient, following the established practice of using thromboembolic prophylaxis for critically ill hospitalized patients, and standard supportive care measures for those with sepsis-induced coagulopathy or DIC. Although D-dimer, sepsis physiology, and consumptive coagulopathy are indicators of mortality, current data do not suggest the use of full-intensity anticoagulation doses unless otherwise clinically indicated. Even though there is an associated coagulopathy with COVID-19, bleeding manifestations, even in those with DIC, have not been reported. If bleeding does occur, standard guidelines for the management of DIC and bleeding should be followed.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Neutrophil extracellular traps in COVID-19

              In severe cases of coronavirus disease 2019 (COVID-19), viral pneumonia progresses to respiratory failure. Neutrophil extracellular traps (NETs) are extracellular webs of chromatin, microbicidal proteins, and oxidant enzymes that are released by neutrophils to contain infections. However, when not properly regulated, NETs have the potential to propagate inflammation and microvascular thrombosis — including in the lungs of patients with acute respiratory distress syndrome. We now report that sera from patients with COVID-19 have elevated levels of cell-free DNA, myeloperoxidase-DNA (MPO-DNA), and citrullinated histone H3 (Cit-H3); the latter 2 are specific markers of NETs. Highlighting the potential clinical relevance of these findings, cell-free DNA strongly correlated with acute-phase reactants, including C-reactive protein, D-dimer, and lactate dehydrogenase, as well as absolute neutrophil count. MPO-DNA associated with both cell-free DNA and absolute neutrophil count, while Cit-H3 correlated with platelet levels. Importantly, both cell-free DNA and MPO-DNA were higher in hospitalized patients receiving mechanical ventilation as compared with hospitalized patients breathing room air. Finally, sera from individuals with COVID-19 triggered NET release from control neutrophils in vitro. Future studies should investigate the predictive power of circulating NETs in longitudinal cohorts and determine the extent to which NETs may be novel therapeutic targets in severe COVID-19. Serum levels of neutrophil extracellular traps identify COVID-19 patients with more severe respiratory disease.
                Bookmark

                Author and article information

                Journal
                J Clin Transl Res
                J Clin Transl Res
                Whioce Publishing Pte. Ltd.
                Journal of Clinical and Translational Research
                Whioce Publishing Pte. Ltd.
                2382-6533
                2424-810X
                06 November 2021
                28 December 2021
                : 7
                : 6
                : 797-808
                Affiliations
                [A1] 1Department of Medicine, St. Thomas Mission Hospital, Kattanam, India
                [A2] 2Department of Pulmonary Medicine, DR KM Cherian Institute of Medical Sciences, Kallissery, India
                [A3] 3Department of Critical Care, Believers Church Medical College Hospital, Thiruvalla, Kerala, India
                [A4] 4Department of Internal Medicine, Saint Vincent Hospital, Worcester, Massachusetts, 01608, USA
                [A5] 5Department of Nuclear Medicine, Christian Medical College, Vellore, India
                [A6] 6Division of Hematooncology, Huntsman Cancer Institute, University of Utah, United States
                [A7] 7Internal Medicine, Warren Apert School of Brown University, Miriam Hospital, 164 Summit Ave, Providence, 02906, RI
                [A8] 8Department of Medicine, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, 200 1 st St SW, Rochester, MN 55905, United States
                [A9] 9Department of Internal Medicine, Division of Cardiology, Saint Vincent Hospital, Worcester, Massachusetts, 01608, USA
                Author notes
                [* ] Corresponding author: Anil Mathew Philip Department of Medicine, St. Thomas Mission Hospital, Kattanam, India. E-mail: anilmathewp@ 123456gmail.com
                Article
                jctres.07.202106.008
                8715711
                34988332
                637aa9ad-8958-4f91-b3eb-2e5adf1cb855
                Copyright: © Whioce Publishing Pte. Ltd.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC-ND 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 20 June 2021
                : 22 August 2021
                : 30 September 2021
                Categories
                Review Article

                coronavirus disease 2019,severe acute respiratory syndrome,coronavirus 2,coronavirus,left ventricular thrombus,acute coronary syndrome,thrombosis,thromboembolism,echocardiogram

                Comments

                Comment on this article